Overview
Animal health firm's Q4 revenue rose 3%, beating analyst expectations
Adjusted EPS for Q4 beat analyst expectations
Company advanced OA pain franchise with new product approvals in Canada and EU
Outlook
Zoetis provides full-year 2026 revenue guidance of $9.825 bln to $10.025 bln
Company expects 3% to 5% organic operational growth in revenue for 2026
Zoetis forecasts adjusted diluted EPS of $7.00 to $7.10 for full year 2026
Result Drivers
U.S. SEGMENT - Revenue decreased 2% due to lower sales of monoclonal antibody products, offset by growth in parasiticides
INTERNATIONAL SEGMENT - Revenue increased 8%, driven by parasiticides and dermatology products
FISCAL YEAR ALIGNMENT - Operational changes contributed to revenue growth in the International segment
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Revenue | Beat | $2.39 bln | $2.36 bln (13 Analysts) |
Q4 Adjusted EPS | Beat | $1.48 | $1.40 (15 Analysts) |
Q4 EPS | $1.37 |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", 7 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Zoetis Inc is $156.44, about 21.6% above its February 11 closing price of $128.67
The stock recently traded at 19 times the next 12-month earnings vs. a P/E of 21 three months ago
Press Release: ID:nBwcc1YSna
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)